Workflow
CHINA ENERGY(00228)
icon
Search documents
新天然气:附属公司中能控股拟供股融资2.39亿港元
Xin Lang Cai Jing· 2025-08-15 08:22
Group 1 - The core point of the article is that Xinjiang Xintai Natural Gas Co., Ltd.'s overseas subsidiary, Zhongneng Holdings (00228.HK), plans to implement a capital restructuring and rights issue [1] - The capital restructuring includes share consolidation, capital reduction, and share split, which will not involve any cash transactions and will not change the equity structure or financial status [1] - The rights issue will be conducted at a ratio of 1 share for every 2 shares held, with a subscription price of HKD 1.57 per share, aiming to raise approximately HKD 239 million for expenses related to the Kashgar North project [1]
港股异动|中能控股(00228)跌超21% 建议股份40合1后二供一 集资最多2.39亿港元
Jin Rong Jie· 2025-08-15 04:06
Group 1 - Zhongneng Holdings (00228) experienced a significant decline, dropping over 21% to 0.04 HKD, with a trading volume of 4.1363 million HKD [1] - The company announced a proposed capital restructuring, suggesting a share consolidation of 40 to 1, followed by a rights issue of up to 152 million shares at a subscription price of 1.57 HKD, representing a discount of 23.04% compared to the theoretical closing price on August 14 [1] - The maximum capital raised from this initiative is expected to be 239 million HKD, with a net amount of 237 million HKD intended for production costs and pipeline transportation fees at the Akmo Wood Gas Field, operational expenses for 3 to 4 existing wells, and the construction of 3 new production wells [1]
港股异动 | 中能控股(00228)跌超21% 建议股份40合1后二供一 集资最多2.39亿港元
Zhi Tong Cai Jing· 2025-08-15 03:01
智通财经APP获悉,中能控股(00228)跌超21%,截至发稿,跌21.57%,报0.04港元,成交额413.63万港 元。 消息面上,中能控股发布公告称,建议资本重组,将股份40合1。生效后进行二供一,发行最多1.52亿 股,供股价1.57港元,较8月14日理论收市价折让23.04%。集资最多2.39亿港元,所得净额2.37亿港元, 拟用作阿克莫木气田的生产成本及管道运输费、3至4个现有措施井及地面工程的营运开支以及建造3个 新生产井。 ...
中能控股跌超21% 建议股份40合1后二供一 集资最多2.39亿港元
Zhi Tong Cai Jing· 2025-08-15 02:59
Group 1 - Zhong Neng Holdings (00228) experienced a significant decline, dropping over 21%, specifically 21.57%, trading at HKD 0.04 with a transaction volume of HKD 4.1363 million [1] - The company announced a proposed capital restructuring, suggesting a share consolidation of 40 to 1. Following this, a rights issue will occur, issuing up to 15.2 million shares at a subscription price of HKD 1.57, which represents a discount of 23.04% compared to the theoretical closing price on August 14 [1] - The maximum capital raised from this initiative is expected to be HKD 239 million, with a net amount of HKD 237 million intended for operational costs related to the Akmo Wood Gas Field, pipeline transportation fees, and expenses for existing measures and new production wells [1]
中能控股(00228)下跌9.8%,报0.046元/股
Jin Rong Jie· 2025-08-15 02:39
Group 1 - The stock price of China Energy Development Holdings Limited (中能控股) dropped by 9.8% on August 15, reaching HKD 0.046 per share with a trading volume of HKD 1.0775 million [1] - The company primarily engages in investment holding and operates a chain of Chinese restaurants in Hong Kong, while also participating in oil and gas production in China through the acquisition of Gongchuang Investment Group [1] - As of the 2024 annual report, the total revenue of China Energy Development Holdings Limited was HKD 278 million, with a net profit of HKD 25.32 million [1] Group 2 - A share consolidation plan of 40-for-1 is scheduled for November 3, 2025 [2] - The company is set to disclose its interim report for the fiscal year 2025 on August 28 [3]
格隆汇公告精选(港股)︱荣昌生物(09995.HK):泰它西普(商品名:泰爱®)治疗原发性乾燥综合征中国III期临床研究达到主要终点
Ge Long Hui· 2025-08-14 14:59
Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]
中能控股(00228)拟实施资本重组,再按“2供1”基准进行供股
Zhi Tong Cai Jing· 2025-08-14 12:24
Group 1 - The company proposes a capital restructuring plan that includes a share consolidation, capital reduction, and share split [1] - The share consolidation will merge every 40 existing shares with a par value of HKD 0.05 into 1 share with a par value of HKD 2.00 [1] - Following the capital reduction, the issued share capital will be reduced, resulting in a credit amount of HKD 593 million to be transferred to the company's paid-in surplus account [1] Group 2 - After the capital restructuring, the board recommends a rights issue at a subscription price of HKD 1.57 per share, offering 1.52 million shares to raise approximately HKD 238.7 million before expenses [2] - If fully subscribed, the estimated net proceeds from the rights issue, after expenses, would be approximately HKD 236.7 million [2] - The company intends to use the net proceeds for additional capital reserves to capture opportunities in the exploration, production, and distribution of natural gas in China [2]
中能控股(00228.HK)建议实施资本重组
Ge Long Hui· 2025-08-14 12:22
Group 1 - The company proposes a capital restructuring plan that includes a share consolidation, capital reduction, and share split [1] - The share consolidation will merge every 40 existing shares with a par value of HKD 0.05 into 1 consolidated share with a par value of HKD 2.00 [1] - The capital reduction will decrease the issued share capital by HKD 1.95 per share, resulting in a total reduction of HKD 593,060,520, which will be transferred to the company's paid-up surplus account [1] Group 2 - Following the capital restructuring, the company plans to conduct a rights issue at a subscription price of HKD 1.57 per share, offering 1 new share for every 2 adjusted shares held by eligible shareholders [2] - The rights issue aims to issue 152,066,800 shares, raising up to approximately HKD 238.7 million before expenses [2] - The net proceeds from the rights issue will be used as additional capital reserves to capture opportunities in the exploration, production, and distribution of natural gas in China [2]
中能控股拟实施资本重组,再按“2供1”基准进行供股
Zhi Tong Cai Jing· 2025-08-14 12:22
Group 1 - The company proposes a capital restructuring plan that includes a share consolidation, capital reduction, and share split [1] - The share consolidation will merge every 40 existing shares with a par value of HKD 0.05 into 1 share with a par value of HKD 2.00 [1] - Following the capital reduction, the issued share capital will be reduced from HKD 2.00 to HKD 0.05, resulting in a credit of HKD 593 million to the company's paid-in surplus account [1] Group 2 - After the capital restructuring, the board recommends a rights issue at a subscription price of HKD 1.57 per share, offering 1 share for every 2 adjusted shares held by eligible shareholders [2] - The rights issue aims to issue 15.2 million shares, raising approximately HKD 238.7 million before expenses [2] - The net proceeds from the rights issue are estimated to be around HKD 236.7 million, intended for additional capital reserves to capture opportunities in China's natural gas exploration, production, and distribution [2]
中能控股(00228) - (1)建议资本重组;(2)建议对章程大纲及章程细则的拟议修订;及 (3)...
2025-08-14 12:10
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責,對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明,並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 本 公 告 僅 供 參 考,並 不 構 成 收 購、購 買 或 認 購 本 公 司 證 券 之 邀 請 或 要 約。 (於 開 曼群島註冊成立之有限公司) (股份代號:228) (1)建 議 資 本 重 組; (2)建 議 修 訂 章 程 大 綱 及 細 則; 及 (3)建議按於記錄日期以非包銷基礎每持有兩(2)股經調整股份 獲發一(1)股供股股份之基準進行供股 建議資本重組 董 事 會 建 議 按 下 列 方 式 實 施 資 本 重 組 包 括 股 份 合 併,資 本 削 減 及 股 份 分 拆: (1) 股份合併 於 緊 隨 資 本 重 組 生 效 前,股 份 合 併 將 按 每 四 十(40)股每股面值0.05港 元 之已發行及未發行現有股份合併為一(1)股每股面值2.00港元之 ...